STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out…
June 3, 2025, 23:04 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 11,500,000…
June 3, 2025, 19:35 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) earlier today informed that the Company has mandated…
June 3, 2025, 17:31 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out…
OssDsign AB (publ) announces that the Annual Report for 2024 is now available as a PDF on the companys website,…
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 1:00…
Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with…
Strong growth and best operating result ever
OssDsign AB (publ) announces that the interim report for Q1 2025 is now available…
STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a…
Uppsala, April 11, 2025. OssDsign® AB (publ.) today announces that a new preclinical study comparing the bone-forming potential of different…
Uppsala, February 25, 2025. OssDsign AB (publ.) today announced that the company has reached its target of 300 enrolled patients…
OssDsign AB (publ.) today announced that the company has appointed Stephen Anderson as Vice President (VP) of Marketing and a…
Reaching milestone in orthobiologics sales
OssDsign AB (publ) announces that the interim report for Q2 2024 is now available as a…
Today, the annual general meeting of 2024 was held in OssDsign AB (publ). Below is a summary of the resolutions…
The board of directors of OssDsign AB, following discussions with a larger group of major shareholders, announces the withdrawal of…
OssDsign AB (publ) announces that the Annual Report for 2023 is now available as a PDF on the companys website,…
Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics…
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00…
Adjusting to other dates in the company’s financial calendar, OssDsign has decided to change the annual report release date to…
Uppsala, Sweden, April 29 – OssDsign AB (publ.) today announces that the company has been awarded a new Veteran Affairs…
OssDsign AB (publ.) today announces that the company’s current VP of Strategy, Business Development and Regulatory Affairs, Tom Buckland, has…